KM-252

N/A

Report date: 2024/10/22 17:01:22

Base Information

Drug NameKM-252
Drug Alias Name重组抗HER2结构域Ⅱ和结构域Ⅳ双特异性抗体注射液KM-252KM252
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Kangming Bio New Drug Development Co LtdXuanzhu (Shijiazhuang) Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Kangming Bio New Drug Development Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A